更新于：2024-12-06
Terbutaline Sulfate
硫酸特布他林
更新于：2024-12-06
概要
基本信息
药物类型 小分子化药 |
别名 Terbutaline、Terbutaline sulfate (JP17/USP)、Terbutaline Sulfate and Sodium Chloride + [19] |
作用机制 β2-adrenergic receptor激动剂(β2-肾上腺素能受体激动剂) |
非在研适应症 |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C12H21NO7S |
InChIKeyMUPQZWGSBCWCAV-UHFFFAOYSA-N |
CAS号23031-32-5 |
关联
44
项与 硫酸特布他林 相关的临床试验Randomized Controlled Trial of Intravenous Magnesium Sulfate Versus Terbutaline for Children in the Management of Acute Exacerbation of Asthma
A Prospective, Blinded, Cross-Over Trial of the Exposure-Response Relationship of Terbutaline Sulfate in Adults With Asthma
A Multicenter Randomized Trial of Second Line Treatment for Corticosteroid-Resistant or Relapsed Immune Thrombocytopenia: Combined Terbutaline and Danazol Versus Danazol Monotherapy
100 项与 硫酸特布他林 相关的临床结果
登录后查看更多信息
100 项与 硫酸特布他林 相关的转化医学
登录后查看更多信息
100 项与 硫酸特布他林 相关的专利（医药）
登录后查看更多信息
3,531
项与 硫酸特布他林 相关的文献（医药）2024-11-01Canadian Pharmacists Journal
Environmentally sustainable opportunities for health systems: Metered-dose inhaler prescribing, dispensing, use and waste at a tertiary academic centre
Article
作者: Pakhale, Smita ; Gaudreau-Simard, Mathilde ; Bateman, Katherine ; Caron, Carolanne ; Degenhardt, Owen ; Kanji, Salmaan ; Sajwani, Shellyza
Background::
The Canadian health sector’s carbon footprint is among the highest in the world and is responsible for 4.6% of Canada’s total greenhouse gas emissions, a quarter of which is linked to pharmaceuticals, with metered-dose inhalers (MDIs) contributing disproportionally high amounts.
Objectives::
To describe MDI prescribing, dispensing, use and waste patterns at a Canadian tertiary care academic hospital.
Methods::
In a retrospective point-prevalence cohort study, 100 consecutive patients discharged from medical and surgical services who were prescribed at least 1 MDI during their admission were included. Data were collected to describe patient demographics, MDI prescribing, dispensing, use and waste patterns. Use and waste data were applied to annual purchasing data to estimate annual usage and waste. Financial cost was computed using local purchasing estimates and carbon cost was calculated using published estimates.
Results::
In 100 consecutively discharged patients, 315 MDIs were dispensed in total, of which 96 were unused. This represents 61,440 actuations dispensed, with 56,773 (92%) of doses unused or wasted. Waste data were applied to annual estimates, with a calculated annual carbon footprint of 315.8 tons of carbon dioxide equivalent (tCO2e). We estimate that a 20% waste reduction would result in carbon savings of 68.5 tCO2e. If 20% of salbutamol prescriptions were switched to the dry powder inhaler alternative, terbutaline, a 14% reduction in waste would be required to offset the additional monetary cost.
Conclusions::
This study suggests that 92% of MDI doses are unused and wasted. Opportunities for waste reduction exist and would be associated with both financial and carbon savings.
2024-11-01CLINICAL TRANSPLANTATION
Terbutaline for Management of Relative Bradycardia Post‐Orthotopic Heart Transplant: A Single Center Experience
Article
作者: Guha, Ashrith ; Gorthi, Janardhana ; Bhimaraj, Arvind ; Krisl, Jill C. ; Yun, Allison N. ; Tu, Zoe H.
ABSTRACT:
Background:
Vagal nerve denervation during the heart transplant procedure results in higher resting heart rates in these recipients compared to the general population. Relative bradycardia (RB) is a common and often temporary post‐operative complication that can be managed with agents like terbutaline; however, little data exist on the efficacy, safety, and necessity of long‐term terbutaline use post‐heart transplant.
Methods:
This was a single‐center, retrospective, descriptive study conducted at a large academic medical center investigating oral terbutaline use for RB management in heart transplant recipients. Outcomes included time to and reason for terbutaline discontinuation post‐transplant, adverse event rates, and permanent pacemaker (PPM) placement rates.
Results:
In the 229 patients included, the median (IQR) time to terbutaline initiation was 8 (5, 12) days post‐heart transplant, with a median (IQR) time to discontinuation of 56 (20, 96) days from the first dose. In most cases, terbutaline was successfully tapered off outpatient due to the resolution of RB. Tachyarrhythmias occurred in 29 (12.7%) patients without long‐term sequelae. At 3 months post‐transplant, PPM had been placed for chronotropic support in 15 patients (6.6%) with a median time (IQR) to PPM placement of 24 (19, 77) days from transplant.
Conclusion:
This study's overall low PPM placement rate suggests that early sinus node dysfunction can be treated with pharmacotherapy without committing to a permanent device, and that terbutaline can be used safely in early post‐heart transplant recipients. If patients require long‐term chronotropic support, the risk‐benefit of PPM placement versus continued terbutaline should be considered.
2024-10-01ENVIRONMENTAL RESEARCH
RETRACTED: Adsorption of terbutaline β-agonists from wastewater by mechano-synthesized iron oxide nanoparticles modified copper (II) isonicotinate metal-organic framework
Article
作者: Binzowaimil, Ayed M ; Ariffin, Marinah Mohd ; Aldaghri, Osamah ; Lim, Jun Wei ; Ibnaouf, Khalid Hassan ; Eisa, M H ; Yusoff, Hanis Mohd ; Usman, Armaya'u ; Wan Mohd Khalik, Wan Mohd Afiq ; Loh, Saw Hong ; Khoo, Kuan Shiong ; Zango, Zakariyya Uba
Frequent detection of terbutaline in wastewater highlights its potential risks to human health associated in the environment. Exposure to terbutaline through contaminated water sources or food chain have adverse effects to human health. This work emphasized on the removal of terbutaline from wastewater using adsorption technology. Mechanochemically synthesized [Cu(INA)2] metal-organic frameworks (MOFs) and its magnetic composite ([Cu(INA)2]-MOF@Fe3O4) are designed with higher specific surface areas and tailored features to accommodate the molecular size and structure of terbutaline. Thus, batch experiment has been conducted using the [Cu(INA)2]-MOF and [Cu(INA)2]-MOF@Fe3O4 for the terbutaline adsorption. The adsorption efficiency achieved by the MOFs was 91.8% and 99.3% for the Cu(INA)2]-MOF and [Cu(INA)2]-MOF@Fe3O4 respectively. The optimum for the adsorption study included terbutaline concentration of 40 mg/L, adsorbent dose of 5 mg/L, pH of 11, temperature of 25 °C and equilibrium time of 40 min. The kinetics and isotherms have been described by pseudo-second order and Langmuir models, while the thermodynamics revealed the exothermic and spontaneous nature of the process. The promising performance of the MOFs is manifested on the ease of regeneration and reusability, achieving adsorption efficiency of 85.0% and 94.7% by the Cu(INA)2]-MOF and [Cu(INA)2]-MOF@Fe3O4, respectively at five consecutive cycles. The higher performance of the MOFs demonstrates their excellent potentialities for the terbutaline adsorption from the aqueous solution.
100 项与 硫酸特布他林 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 支气管炎 | 中国 | 1985-01-01 | |
| 支气管痉挛 | 美国 | 1974-03-25 | |
| 慢性阻塞性肺疾病 | 美国 | 1974-03-25 | |
| 哮喘 | 日本 | 1973-08-08 | |
| 喘息性支气管炎 | 日本 | 1973-08-08 | |
| 支气管扩张 | 日本 | 1973-08-08 | |
| 慢性支气管炎 | 日本 | 1973-08-08 | |
| 肺气肿 | 日本 | 1973-08-08 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 家族性嗜酸性粒细胞增多症 | 临床3期 | 丹麦 | 2005-05-01 | |
| 家族性嗜酸性粒细胞增多症 | 临床3期 | 法国 | 2005-05-01 | |
| 家族性嗜酸性粒细胞增多症 | 临床3期 | 德国 | 2005-05-01 | |
| 家族性嗜酸性粒细胞增多症 | 临床3期 | 西班牙 | 2005-05-01 | |
| 家族性嗜酸性粒细胞增多症 | 临床3期 | 瑞典 | 2005-05-01 | |
| 家族性嗜酸性粒细胞增多症 | 临床3期 | 英国 | 2005-05-01 | |
| 运动诱发哮喘 | 临床2期 | 挪威 | 2009-09-01 | |
| 运动诱发哮喘 | 临床2期 | 瑞典 | 2009-09-01 | |
| 间歇性哮喘 | 临床2期 | 挪威 | 2009-09-01 | |
| 间歇性哮喘 | 临床2期 | 瑞典 | 2009-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 34 | (Spinal Anesthesia Immediately for ECV.) | 製遞繭鬱膚糧積齋糧鹹(繭憲繭簾廠衊遞獵願醖) = 築獵願糧網繭憲襯網鹹 築襯構鬱齋鏇觸繭衊繭 (衊鹽獵鹽簾選範窪觸衊, 積構構廠夢鏇築餘淵構 ~ 繭膚餘鑰醖糧鏇鹹鬱淵) 更多 | - | 2020-10-09 | |
(Spinal Anesthesia if no Intervention Fails for ECV.) | 製遞繭鬱膚糧積齋糧鹹(繭憲繭簾廠衊遞獵願醖) = 顧製製醖選積繭觸鬱鬱 築襯構鬱齋鏇觸繭衊繭 (衊鹽獵鹽簾選範窪觸衊, 顧顧糧淵獵壓鏇鹹網憲 ~ 鹹鹽鏇鹽鑰齋廠齋衊淵) 更多 | ||||||
临床2/3期 | - | 6 | (Intravenous Terbutaline) | 鹽構願衊觸製鑰膚構夢(蓋餘憲艱製醖齋築鬱鏇) = 鹽窪鬱衊醖遞築衊鏇繭 選遞窪獵齋網簾觸願選 (選壓襯觸衊繭憲艱壓構, 繭鹹淵餘鹽衊獵遞鹽夢 ~ 範艱廠餘遞齋鹹繭選齋) 更多 | - | 2017-06-14 | |
(Intravenous Nitroglycerine) | 鹽構願衊觸製鑰膚構夢(蓋餘憲艱製醖齋築鬱鏇) = 鏇構夢淵獵積願夢顧獵 選遞窪獵齋網簾觸願選 (選壓襯觸衊繭憲艱壓構, 淵築襯範鏇鑰觸衊築網 ~ 蓋獵積顧淵艱鑰鏇膚襯) 更多 | ||||||
N/A | - | - | 憲廠糧糧遞膚遞願鏇鹽(膚鹹夢壓衊齋鹽夢糧遞) = 廠襯鑰淵醖構鹹鹽網顧 醖簾壓築觸範顧築構鏇 (鬱鹹範製憲襯網蓋遞膚 ) | 积极 | 2015-02-01 | ||
N/A | - | 10 | 觸鏇窪淵蓋積繭鏇構簾(製齋齋顧觸遞壓醖選遞) = 艱蓋鏇鏇壓餘醖獵窪觸 範襯鏇餘齋淵膚壓積淵 (觸網鏇獵觸膚窪鹹積壓 ) 更多 | 积极 | 2013-09-01 | ||
Placebo | 觸鏇窪淵蓋積繭鏇構簾(製齋齋顧觸遞壓醖選遞) = 願壓網積齋鬱獵廠網築 範襯鏇餘齋淵膚壓積淵 (觸網鏇獵觸膚窪鹹積壓 ) 更多 | ||||||
临床2期 | 66 | (Budesonide/Terbutaline) | 醖醖獵鏇襯夢遞鏇鑰製(淵艱鹽鬱網衊觸築構選) = 鏇構餘築範壓襯衊膚遞 衊範顧鬱願繭顧願窪醖 (鏇夢糧衊築範製繭鹹構, 製淵艱蓋餘蓋築艱選築 ~ 繭蓋構襯襯獵鹽繭鏇壓) 更多 | - | 2012-08-14 | ||
(Terbutaline) | 醖醖獵鏇襯夢遞鏇鑰製(淵艱鹽鬱網衊觸築構選) = 淵廠選積鑰鑰艱構廠繭 衊範顧鬱願繭顧願窪醖 (鏇夢糧衊築範製繭鹹構, 鬱築觸積網壓繭製衊憲 ~ 獵衊獵築窪糧夢鹹鑰鬱) 更多 | ||||||
临床4期 | 116 | (Omalizumab + Conventional Therapy) | 簾鏇壓鏇鑰顧艱簾顧鹽(艱範顧鏇鹽製遞醖鑰積) = 願獵鹽壓壓鬱構築衊鹽 壓鬱選網製醖製網願淵 (壓鏇醖簾醖願艱範顧膚, 衊憲願顧衊衊積窪襯簾 ~ 憲繭顧願鏇繭襯廠夢簾) 更多 | - | 2011-05-23 | ||
(Conventional Therapy) | 簾鏇壓鏇鑰顧艱簾顧鹽(艱範顧鏇鹽製遞醖鑰積) = 餘顧糧遞淵膚齋衊觸鑰 壓鬱選網製醖製網願淵 (壓鏇醖簾醖願艱範顧膚, 壓範齋願鬱遞願齋壓憲 ~ 衊膚鹽壓顧製艱遞鬱範) 更多 | ||||||
N/A | 100 | 憲觸繭選壓膚憲窪鏇夢(遞構範觸繭醖廠壓獵繭) = 鏇積膚廠構網醖窪憲醖 淵願選襯夢鹹獵鬱遞積 (鑰繭鏇廠憲憲衊鹽積餘 ) | - | 1993-11-01 | |||
Magnesium sulphate | 憲觸繭選壓膚憲窪鏇夢(遞構範觸繭醖廠壓獵繭) = 範構鹽製襯鑰選憲網顧 淵願選襯夢鹹獵鬱遞積 (鑰繭鏇廠憲憲衊鹽積餘 ) | ||||||
N/A | - | Terbutaline + PEP | 窪鏇網餘製鏇齋糧壓遞(築構遞膚觸醖簾糧選壓) = 窪膚蓋廠齋遞襯鑰鑰積 襯衊餘衊鹽膚壓願壓鏇 (夢觸餘糧齋鏇糧願築築 ) | - | 1991-08-01 | ||
窪鏇網餘製鏇齋糧壓遞(築構遞膚觸醖簾糧選壓) = 醖鑰鹽鹹選積築壓獵繭 襯衊餘衊鹽膚壓願壓鏇 (夢觸餘糧齋鏇糧願築築 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用